Top Line
Coronavirus mutations that confer resistance to the antiviral drug remdesivir were found in an immunocompromised patient who had previously been treated with the drug, researchers have found, leading to a higher incidence of COVID-19 in patients with persistent disease. raises concerns about the possible emergence of drug-resistant versions. ,
- Advertisement -
Remdesivir was one of the first drugs approved for the treatment of COVID-19 in hospitalized patients.
important facts
- Advertisement -
in a preprint study published On Medrixiv, researchers found that a woman in her 70s who was treated with the drug failed to completely clear her COVID-19 infection for several months.
A genetic test for the virus revealed that it had mutated during treatment in a way that reduced the effectiveness of the antiviral drug Gilead-manufactured.
According to One of the study’s authors, Professor Akiko Iwasaki, said remdesivir initially reduced the patient’s viral load, but it increased again during remdesivir treatment.
According to the study, persistent infections were eventually successfully treated using monoclonal antibodies.
The woman exhibiting the mutation was immunized because she had previously been treated for non-Hodgkin’s lymphoma.
,
- Advertisement -
